Sung Lee | Vice President of Investor Relations |
Robin Washington | Executive Vice President and Chief Financial Officer |
Laura Hamill | Executive Vice President, Worldwide Commercial Operations |
John McHutchison | Chief Scientific Officer and Head of Research and Development |
Gregg Alton | Interim Chief Executive Officer and Chief Patient Officer |
Geoff Meacham | Barclays |
Michael Yee | Jefferies |
Brian Abrahams | RBC Capital Markets |
Geoffrey Porges | Leerink |
Matthew Harrison | Morgan Stanley |
Robyn Karnauskas | Citi |
Alethia Young | Cantor Fitzgerald |
Umer Raffat | Evercore ISI |
Cory Kasimov | JPMorgan |
Phil Nadeau | Cowen and Company |
Salim Syed | Mizuho Securities |
Terence Flynn | Goldman Sachs |
Ying Huang | Bank of America Merrill Lynch |
Carter Gould | UBS |
Ladies and gentlemen, thank you for standing by, and welcome to Gilead Sciences Fourth Quarter 2018 Earnings Conference Call. My name is Jonathan. I will be your conference operator today. At this time, all participants are in a listen-only mode. And as a reminder, this conference call is being recorded.